Integra Lifesciences Holdings (IART) Operating Expenses (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Operating Expenses data on file, last reported at $380.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 4.45% year-over-year to $380.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 billion (up 30.68% YoY), and the FY2025 full-year result was $2.1 billion, up 34.54% from the prior year.
• Operating Expenses slipped to $380.4 million in Q1 2026, from $411.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $928.3 million in Q2 2025 to a low of $320.1 million in Q3 2022.
• A 5-year average of $402.4 million and a median of $368.8 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses retreated 4.93% in 2022 and surged 120.39% in 2025, its largest moves.
• Tracing IART's Operating Expenses over 5 years: stood at $330.2 million in 2022, then increased by 9.33% to $361.0 million in 2023, then grew by 12.75% to $407.0 million in 2024, then gained by 1.2% to $411.9 million in 2025, then decreased by 7.63% to $380.4 million in 2026.
• Business Quant data shows IART's Operating Expenses at $380.4 million in Q1 2026, $411.9 million in Q4 2025, and $390.3 million in Q3 2025.